Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe

  Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF
  Biosimilar Product Candidates in Europe

  – Biogen Idec Opts-In to Commercialization Opportunity with Joint Venture
                                  Partner –

Business Wire

CAMBRIDGE, Mass. & SEOUL, Korea -- December 17, 2013

Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through
their joint venture, Biogen Idec has exercised its right to enter into an
agreement to commercialize anti-TNF biosimilar product candidates in Europe,
including biosimilars for widely used therapies to treat conditions such as
rheumatoid arthritis and Crohn’s disease.

Under the agreement, Biogen Idec will be responsible for commercialization of
these product candidates across Europe, where there already exists a strong
market for biosimilars and a defined regulatory pathway. The agreement with
Samsung Bioepis aligns with Biogen Idec’s broader corporate objectives of
remaining focused on its core business, while leveraging its expertise in
manufacturing and specialty markets to meet the need for biosimilar therapies.

“This is a unique opportunity for us to leverage our experience in developing
and manufacturing high-quality biologics in therapeutic areas where we are
deeply focused, and provide medicines to patients where there is a significant
societal need,” said Tony Kingsley, executive vice president of global
commercial operations for Biogen Idec. “As a company that aims to make a
difference in the lives of patients with serious diseases, we are excited by
the potential to offer additional highly effective therapies in critical areas
where there is growing demand.”

“Biogen Idec has been an innovative joint venture partner in Samsung Bioepis
and now with this agreement we are excited to extend our relationship into
commercial operations,” said Christopher Hansung Ko, Ph.D., CEO of Samsung
Bioepis. “Samsung Bioepis has established a global commercialization plan for
its antibody drugs currently under development, and we believe this agreement
will further serve as a solid foundation for Samsung Bioepis to develop into a
worldwide biosimilar leader.”

About Biogen Idec

Through cutting-edge science and medicine,Biogen Idecdiscovers, develops and
delivers to patients worldwide innovative therapies for the treatment of
neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in
1978,Biogen Idecis the world’s oldest independent biotechnology company.
Patients worldwide benefit from its leading multiple sclerosis therapies, and
the Company generates more than$5 billionin annual revenues. For product
labeling, press releases and additional information about the Company, please
visitwww.biogenidec.com.

About Samsung Bioepis

Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec,
aims to develop affordable and high-quality biopharmaceutical and biosimilar
products. For more information, please visit www.samsungbioepis.com.

Biogen Idec Safe Harbor Statement

This press release contains forward-looking statements, including statements
regarding our expectations and potential to offer biosimilar product
candidates to patients in Europe. These forward-looking statements may be
accompanied by such words as "anticipate," "believe," "estimate," "expect,"
"forecast," "intend," "may," "plan," "will" and other words and terms of
similar meaning. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such statements,
including the risk that regulatory authorities may require additional
information or further studies or may fail to approve or may delay approval of
any potential new therapy, the risk that we fail to comply with government
regulation or changes in such regulation, product reimbursement may be limited
or unavailable, there may be problems with manufacturing processes,
intellectual property rights may not be adequately protected, risks of
infringement of intellectual property rights of third parties, risks
associated with our dependence on third parties for the development and
commercialization of biosimilars, adverse safety events may occur, the risk
that we encounter other unexpected hurdles or difficulties, and the other
risks and uncertainties that are described in the Risk Factors section of our
most recent annual or quarterly report filed with theSecurities and Exchange
Commission. These statements are based on current beliefs and expectations and
speak only as of the date of this press release. We do not undertake any
obligation to publicly update any forward-looking statements.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20131216006278/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50769575&lang=en

Contact:

MEDIA CONTACT:
Biogen Idec
Jason Glashow, 781-464-3260
or
Annabel Cowper, +41 41 392 1702
public.affairs@biogenidec.com
or
INVESTOR CONTACT:
Biogen Idec
Carlo Tanzi, Ph.D., 781-464-2442
IR@biogenidec.com
or
MEDIA CONTACT:
Samsung Bioepis
Hongseok Ji, Ph.D., +82 (32) 455-6102
hsji@samsung.com
or
INVESTOR CONTACT:
Samsung Bioepis
Sungjoon Park, +82 (32) 455-6120
sj4.park@samsung.com
 
Press spacebar to pause and continue. Press esc to stop.